Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 142-147

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.142147

Advances in Bioresearch

REVIEW ARTICLE

Renal Fibrosis Mechanisms: Insights into Therapeutic Targets

[1]Iype Cherian, [2]Harisinh Parmar, [3*]Bammidi Rohit Kumar, [4]Abhijit Nashte, [5]Aparna Patange,
1,2 Dept. of Neurology,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India
3-5Department of Medicine, Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra
*Corresponding Author

ABSTRACT
Renal fibrosis, a characteristic of chronic kidney disease (CKD), is caused by an excessive build-up of extracellular matrix in the renal parenchyma. It is a complicated pathological process. This fibrotic change is brought on by a variety of stressors, including diabetes, hypertension, and glomerulonephritis. The end result is irreversible tissue scarring, impaired renal function, and ultimately organ failure. Comprehending the complex cellular and molecular processes behind renal fibrosis is essential for creating tailored treatment approaches. The promotion of fibrogenesis in the kidney is primarily driven by the epithelial-mesenchymal transition (EMT), myofibroblast activation, and dysregulated cytokine signalling pathways, especially the transforming growth factor-beta (TGF-β) cascade. The pathophysiology of chronic kidney disease (CKD) is influenced by the interaction of immune cells, profibrotic mediators, and resident renal cells, which sustains the fibrotic response. Although there have been breakthroughs, there are still few therapeutic alternatives that particularly target renal fibrosis, which highlights the need for new treatment approaches. There are several interesting strategies to interfere with the fibrotic process, including modifying immunological responses, targeting important biochemical pathways, and investigating novel drug delivery techniques. Preclinical discoveries are still difficult to translate into successful clinical outcomes, which emphasises the need for strong biomarkers and personalised medicine strategies for early identification and prognosis. Using patient-specific data, combinatorial medicines and precision medicine present themselves as viable approaches to managing the heterogeneity of renal fibrosis and enhancing therapy results.
***Keywords**: Renal fibrosis, chronic kidney disease, fibrogenesis, therapeutic interventions, precision medicine.*

Received 24.11.2023 Revised 01.12.2023 Accepted 21.02.2024

How to cite this article:
Iype C, Harisinh P, Bammidi R K, Abhijit N, Aparna P. Renal Fibrosis Mechanisms: Insights into Therapeutic Targets. Adv. Biores., Vol 15 (2) March 2024: 142-147.

INTRODUCTION

One of the main pathological processes causing chronic kidney disease (CKD) to proceed over time across different aetiologies is renal fibrosis, which eventually leads to permanent organ damage and dysfunction [1]. Renal fibrosis is characterised by an excessive build-up of extracellular matrix (ECM) proteins in the renal glomeruli and interstitium. This condition causes tissue scarring, function loss, and ultimately renal failure [2]. The common route frequently converges at the fibrotic endpoint despite a variety of main insults, such as diabetes, hypertension, glomerulonephritis, and obstructive uropathy [3]. This indicates the necessity for thorough investigation of the underlying processes behind this complex process.

An abnormal wound healing response to repeated insults is the driving force behind the complex interaction of several cellular and molecular processes that comprise the complicated pathophysiology of renal fibrosis [4]. Renal parenchymal cells, mainly tubular epithelial cells, change phenotypically. One important process that occurs during this transition is called the epithelial-mesenchymal transition (EMT), which is when epithelial cells take on mesenchymal traits and become part of the myofibroblast pool, which is the main effector cell in fibrogenesis [5]. Many signalling pathways and mediators play a role in orchestrating this transformation, with transforming growth factor-beta (TGF-β) being a major driver [6].

By promoting fibroblast activation, causing ECM synthesis, and inhibiting ECM degradation, the canonical TGF-β pathway acts as a master regulator in renal fibrosis, shifting the scales in favour of fibrotic

deposition [7]. Simultaneously, the complex interplay between indigenous renal cells and immune cells plays a major role in the fibrotic process. Immune cells that infiltrate the body, such as lymphocytes, dendritic cells, and macrophages, produce chemokines and cytokines that promote inflammation and fibrosis [8].

Moreover, fibrogenesis is sustained by a multitude of other molecular actors, such as platelet-derived growth factor (PDGF), nuclear factor-kappa B (NF-κB), and connective tissue growth factor (CTGF), all of which contribute to the amplification and upkeep of the fibrotic cascade [9].

Even with the wealth of information that has been gathered in recent years, there are still few pharmacological approaches that target renal fibrosis specifically [10]. The primary goals of clinical care are symptom management and the mitigation of underlying aetiologies. This emphasises the pressing need to identify new targets for therapeutic intervention and to stop or reverse the fibrotic process.

Understanding the complexity of renal fibrosis is fraught with difficulties. The complex interactions between various cell types, signalling pathways, and environmental signals present a significant challenge in the development of tailored treatments. Furthermore, the variability of fibrotic disorders among patients calls for a customised approach to treatment plans. Furthermore, preclinical medication development and validation are hampered by the paucity of reliable translational models that accurately capture the complex features of human renal fibrosis [1,3].

However, new developments in omics technologies, including as transcriptomics, proteomics, metabolomics, and genomes, present encouraging paths for identifying novel biomarkers and treatment targets [6-10]. By utilising these developments, precision medicine has the ability to pinpoint patient-specific weaknesses and customise treatment plans for better results.

The renal fibrosis, which emerges as a convergent route leading to end-stage kidney disease, is a complicated and incapacitating result of several renal insults. To aid in the creation of successful treatment interventions, a comprehensive understanding of the fibrotic process is essential because to the complex interactions between cellular, molecular, and environmental components. It is possible to lessen the effects of renal fibrosis and enhance clinical outcomes for those who are impacted by the condition by addressing the issues and utilising cutting-edge technologies.

Section 1: Renal Fibrosis Cellular Mechanisms

Renal fibrosis is a complex and dynamic process that is controlled by several cellular processes that take place in the renal microenvironment. The epithelial-mesenchymal transition (EMT), a process known as the phenotypic transformation of tubular epithelial cells, is crucial to fibrogenesis [1]. Quiescent tubular epithelial cells go through phenotypic changes during the crucial biological process known as epithelial-mesenchymal transition (EMT), losing their epithelial properties and gaining mesenchymal ones [2].

As a result of this phenotypic plasticity, epithelial cells become active myofibroblasts and lose cell-cell adhesion molecules like E-cadherin. Mesenchymal markers like α-SMA and fibroblast-specific protein-1 (FSP-1) are also expressed more often [3]. These myofibroblasts are important agents in the synthesis and deposition of extracellular matrix, which promotes kidney fibrosis.

There is ongoing research and discussion over the genesis of myofibroblasts in renal fibrosis. Although myofibroblasts have historically been linked to resident fibroblasts, new research indicates that a sizable fraction of these cells may originate from tubular epithelial cells during their EMT [4]. This dynamic process highlights the intricate interactions between various renal cell types and illustrates the cellular plasticity inherent in renal fibrosis.

Moreover, a crucial stage in the process of fibrogenesis is the activation of fibroblasts into myofibroblasts. Profibrotic substances, including TGF-β, CTGF, and PDGF, activate quiescent fibroblasts in the interstitium and cause them to differentiate into myofibroblasts [5]. Myofibroblasts are the main source of extracellular matrix (ECM) components, including as collagen, fibronectin, and proteoglycans, after they are activated. This results in the excessive matrix deposition that is typical of fibrotic kidneys [6].

Recent years have seen a notable increase in the study of the interaction between renal endothelial cells and fibrosis. The fibrotic process is facilitated by endothelial dysfunction, which is characterised by reduced vasodilation, elevated vascular permeability, and altered angiogenic responses [7]. Renal damage is further prolonged by tissue hypoxia caused by the loss of peritubular capillaries and capillary rarefaction in the renal parenchyma [8]. This promotes a pro-fibrotic milieu.

Furthermore, immune cells that have infiltrated the body actively contribute to the fibrotic cascade. Specifically, macrophages display a variety of phenotypes and have specific functions in renal fibrosis. While alternatively activated (M2) macrophages perform reparative tasks by encouraging ECM turnover and the resolution of inflammation, classically activated (M1) macrophages release pro-inflammatory cytokines, aggravating tissue damage [9]. The overall fibrotic response in the kidney is influenced by the fine balance between these phenotypes of macrophages.

Renal fibrosis is sustained by a dynamic biological milieu made up of tubular epithelial cells, immunological cells, fibroblasts/myofibroblasts, and endothelial cells interacting intricately [10]. Numerous signalling molecules and cytokines facilitate crosstalk between various cellular constituents, which aids in the maintenance and advancement of the fibrotic process.

To disrupt important pathways implicated in renal fibrogenesis, tailored therapeutic approaches must be developed, which requires an understanding of the complexities of these cellular interactions. The particular roles played by each cell type and their interactions will need to be better understood in order to develop new therapeutic targets that might stop or reverse the kidney's fibrotic process.

Section 2: Renal Fibrosis and Molecular Signalling Pathways

Renal fibrosis is controlled by molecular signalling pathways, which set off a series of events that lead to the deposition of extracellular matrix (ECM) proteins and the eventual loss of renal function. The transforming growth factor-beta (TGF-β) signalling pathway is a key mediator among these pathways, having a significant impact on a number of cellular processes that contribute to fibrosis [1].

TGF-β, which comes in three isoforms (TGF-β1, TGF-β2, and TGF-β3), uses both canonical and non-canonical pathways to promote fibritin [2]. SMAD2 and SMAD3, two intracellular mediators known as SMAD proteins, are phosphorylated when TGF-β interacts to their receptors (TGF-βRI and TGF-βRII) in the canonical route. These SMAD complexes that have been activated go into the nucleus, where they alter gene transcription and encourage fibrotic reactions [3].

Furthermore, TGF-β signalling increases the fibrotic milieu by interacting with several additional molecular pathways. It promotes myofibroblast activation, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK via crosstalk with mitogen-activated protein kinase (MAPK) pathways [4].

Apart from TGF-β, inflammatory cytokines are essential in causing renal fibrosis. The kidney's pro-inflammatory milieu, which stimulates fibroblast activation and the creation of extracellular matrix (ECM), is constituted by tumour necrosis factor-alpha (TNF-α), interleukins (IL-1, IL-6, IL-18), and chemokines (CCL2, CXCL12) [5]. These cytokines work through complex signalling pathways, such as NF-κB, which is a key modulator of fibrosis and inflammation. The fibrotic cascade is sustained by pro-inflammatory and profibrotic genes that are expressed as a result of NF-κB activation [6].

Retinal fibrosis is linked to several cellular processes that are modulated by connective tissue growth factor (CTGF), which is another important mediator [7]. Functioning as a downstream effector of TGF-β, CTGF augments extracellular matrix formation, encourages myofibroblast activation, and plays a role in the maintenance of the fibrotic response. The complex relationships it has with different signalling pathways, such as TGF-β and Wnt/β-catenin, intensify the fibrogenic signals in the kidney even more.

Furthermore, the advancement of renal fibrosis has been linked to dysregulated signalling through the Wnt/β-catenin pathway [8]. Activation of canonical Wnt signalling results in the stabilisation and nuclear translocation of β-catenin, which in turn causes changes in the gene expression patterns linked to fibrosis. The synergistic functions of TGF-β and Wnt signalling pathways in generating renal fibrogenesis are highlighted by their notable cross-talk, which increases profibrotic responses.

Renin-angiotensin-aldosterone system (RAAS) involvement is also crucial in the pathophysiology of renal fibrosis [9]. Renal damage and fibrosis are fostered by angiotensin II, a crucial RAAS effector molecule that stimulates oxidative stress, inflammation, and the synthesis of extracellular matrix (ECM) via its receptors. An essential part of managing renal fibrosis and the advancement of CKD is targeting elements of the RAAS, such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

Comprehending the complex interactions between various molecular signalling pathways serves as a foundation for creating focused therapies that try to interfere with or alter certain pathways in order to lessen renal fibrosis. The fibrotic process can potentially be stopped or reversed by therapeutic approaches that target important molecular actors in these pathways, protecting renal function and slowing the advancement of the illness.

Section 3: Renal Fibrosis Therapeutic Targets

A potential approach to creating therapeutic treatments meant to slow the course of the illness and maintain renal function is to target certain cellular processes and molecular pathways linked to renal fibrosis. A thorough comprehension of these targets is essential for developing treatments that effectively stop or reverse the kidney's fibrotic process.

Aiming for the Transforming Growth Factor-Beta (TGF-β) Route

Considering its pivotal function in fostering fibrogenesis, several methods have been investigated for adjusting TGF-β signalling. Preclinical research has demonstrated the potential of inhibitors that target TGF-β receptors or downstream SMAD signalling, since they have been able to successfully reduce

fibrosis in animal models [1]. But because TGF-β signalling is intricate and multidimensional, care must be taken to prevent unfavourable systemic consequences.

Strategies to Reduce Inflammation

Renal fibrosis is mostly driven by inflammation. Targeting pro-inflammatory cytokines like TNF-α and interleukins with therapeutic therapies has been studied. Although anti-TNF medications have not consistently been able to stop the advancement of fibrosis, clinical trials investigating their effectiveness have demonstrated promise in lowering inflammation [2]. Innovative methods that alter certain inflammatory pathways are being studied to reduce fibrotic reactions without jeopardising host defence systems.

Fibroblast Activation and ECM Synthesis Modulation

Techniques to reduce ECM production and fibroblast activation have attracted a lot of interest. Targeting important mediators of fibroblast activation including PDGF and CTGF as well as downstream effectors of profibrotic pathways, small molecule inhibitors are being investigated [3]. By explicitly interfering with ECM production and deposition, these strategies seek to break the fibrotic cascade.

The modulation of immunity

One interesting approach to addressing renal fibrosis is to alter the immune response in the kidney. Strategies that target certain immune cell populations—like macrophages—strive to shift their phenotypes from reparative (M2) to pro-inflammatory (M1) in order to foster an environment that is anti-fibrotic [4]. Additionally, medications that control the recruitment of immune cells into the kidney or the release of inflammatory mediators are currently being investigated.

Inhibition of the Renin-Angiotensin-Aldosterone System (RAAS)

Since the RAAS is essential to the pathophysiology of renal fibrosis, therapeutic intervention targeting it is very desirable. Keystones in the treatment of CKD and renal fibrosis are medications that target elements of the RAAS, such as ARBs and ACEIs [5]. The advancement of fibrosis has been beneficially slowed by their capacity to reduce oxidative stress, ECM deposition, and inflammation mediated by angiotensin II.

New Approaches to Drug Delivery and Biomaterials

New developments in biomaterials and medication delivery technologies provide creative ways to address renal fibrosis. Targeted administration of medicinal drugs to certain renal cells or compartments is made possible by nanoparticle-based drug delivery systems, which maximise medication effectiveness while reducing off-target effects [6]. Hydrogels and scaffolds are examples of biomaterials that show promise in stimulating tissue regeneration and altering the renal milieu to prevent fibrosis.

Methods in Personalised Medicine

Because each person with renal fibrosis is unique, treatment must be tailored to each patient. Through the use of biomarkers and omics technology, advances in precision medicine seek to pinpoint patient-specific vulnerabilities so that treatments may be customised appropriately [7]. The creation of more specialised and effective therapies may be made possible by classifying patients according to their molecular profiles or disease phenotypes.

To sum up, a wide range of treatment targets and approaches have been investigated in relation to renal fibrosis. Although a great deal of work has been made in understanding the underlying processes, it is still difficult to translate these discoveries into therapeutically useful medicines. In order to create targeted medicines that can successfully stop or reverse the fibrotic process inside the kidney, further research and creative techniques are required due to the multifactorial nature of renal fibrosis and the complex interplay among cellular and molecular pathways.

Section 4: Renal Fibrosis Research Using Experiments Models

In order to understand the intricate processes behind renal fibrosis, experimental models are a useful resource. These models seek to summarise important facets of the pathophysiology of the illness, offering understanding of cellular and molecular interactions, aiding in the creation of new drugs, and permitting the assessment of possible therapeutic treatments.

Unilateral Ureteral Blockage (UUO) Framework

One of the most widely used experimental models of renal fibrosis is the UUO model, which entails surgically blocking or ligating one ureter to cause a range of pathophysiological alterations that are similar to those seen in obstructive nephropathy in humans [1]. This model is useful for investigating both early and late-stage fibrotic processes because it replicates renal damage, interstitial inflammation, tubular atrophy, and progressive fibrosis.

Model of Ischemia-Reperfusion Injury (IRI)

Ischemia-reperfusion damage mimics the clinical processes observed in acute kidney injury (AKI) and renal transplantation. It is characterised by a brief stoppage of renal blood flow followed by reperfusion

[2]. This model allows for the analysis of early events leading to fibrotic responses by inducing inflammation, oxidative stress, and eventual fibrosis.

Transgenic and Genetic Models

Important insights into the processes behind renal fibrosis have been gained via genetically engineered animal models, such as transgenic mice and knockout models that target certain genes or signalling pathways implicated in the illness [3]. These models provide prospects for targeted therapeutic treatments by enabling researchers to clarify the involvement of certain genes or proteins in fibrogenesis.

Models of Chronic Kidney Disease (CKD)

Chronic assaults such nephrotoxins, high-fat diets, or long-term drug administration like adenine or aristolochic acid mimic human CKD-related kidney damage and fibrosis in experimental models [4]. By simulating the chronicity and variety of real renal fibrosis, these models offer a platform for researching the course of the illness and testing possible treatments.

Models of Renal Ischemia

The investigation of hypoxia-driven fibrotic responses in the kidney is made possible by models that imitate vascular disorders or diminished renal perfusion and can be used to induce chronic renal hypoxia [5]. These models concentrate on the effects of prolonged ischemia and the ensuing hypoxia on the molecular and cellular mechanisms that lead to renal fibrosis.

Organoids and Cells Derived from Patients

A customised platform for researching disease causes and assessing treatment responses in a patient-specific setting is provided by including renal organoids made from induced pluripotent stem cells (iPSCs) or patient-derived cells [6]. By making it easier to evaluate individual differences in the course of a disease and the effectiveness of a treatment, these models open the door to personalised medical techniques.

Restrictions and Prospective Paths

Although useful, experimental models are inherently limited. Translation of research results to therapeutic applications is hampered by species variability, variations in disease presentation from human pathology, and the incapacity to fully encapsulate the complexity of human renal fibrosis [7]. Preclinical findings may thus be more broadly applicable if many models are combined and human-relevant components—like kidney slices or cells generated from patients—are included.

To sum up, renal fibrosis experimental models have made a substantial contribution to our knowledge of the aetiology of the illness and available treatment options. Together, these models—each with advantages and disadvantages—offer a framework for deciphering complex cellular and molecular pathways, assessing potential new targets for treatment, and bridging the gap between preclinical and clinical research.

Section 5: Obstacles and Prospects for Renal Fibrosis

Individualization and Heterogeneity in Medicine

Individuals with renal fibrosis vary greatly in the aetiology, pathophysiology, and course of the illness. This variety makes creating consistent treatment plans extremely difficult. Personalised medicine techniques, which make use of patient-specific data such as transcriptomics, genomes, and clinical phenotypes, have the potential to customise therapies for individual patients [1]. Finding certain biomarkers or molecular signatures linked to various fibrotic phenotypes may help direct focused treatments and enhance therapy results.

Clinical Trials and the Translational Gap

One of the primary obstacles to further research on renal fibrosis is the translational gap that exists between preclinical discoveries and clinical success. Many treatment options fall short of clinical trial effectiveness while showing promise in preclinical animals [2]. In order to close this gap, preclinical models must be improved in order to more accurately represent the intricacies of human illness. Additionally, new targets and clinical therapies must be thoroughly validated.

Combinatorial Therapies and Their Multifactorial Nature

Multifactorial assaults that include complex interactions across different cellular and molecular pathways are the cause of renal fibrosis. It might not be possible to successfully stop the complex fibrotic process by focusing on only one channel. Combinatorial treatments are one possible approach to combat the complexity of renal fibrosis. These therapies involve the simultaneous targeting of numerous pathways or the use of medicines with synergistic effects [3]. Optimising medication combinations while reducing side effects is still difficult, though.

Biomarkers for Prognosis and Early Detection

For prompt management and better patient outcomes, renal fibrosis must be identified early and accurately predicted. Finding trustworthy biomarkers for the beginning, course, or response to treatment

of a disease is a continuous task [4]. Investigating new blood or urine biomarkers, molecular signatures, and non-invasive imaging techniques may help diagnose and track the evolution of renal fibrosis in clinical settings.

Cutting-Edge Therapeutic Delivery Systems

Novel drug delivery strategies are being investigated to improve therapeutic agents' specificity and effectiveness for treating renal fibrosis. Targeted drug conjugates, drug-loaded scaffolds, and nanoparticle-based delivery methods have the potential to provide precise and long-lasting drug release inside the kidney, reducing systemic toxicity and optimising local therapeutic benefits [5]. By removing obstacles connected with traditional medication distribution, these developments have the potential to completely transform the way anti-fibrotic medicines are delivered.

Artificial Intelligence and Digital Health Integration

Utilising wearable technology, AI-powered analytics, and electronic health records are just a few examples of how digital health technologies are integrating to improve illness monitoring and treatment optimisation [6]. AI systems that examine clinical factors and multi-omics data may be able to help with illness progression prediction, new target discovery, and customised treatment plan optimisation.

Collaboration and Research Focused on Patients

The advancement of renal fibrosis research is contingent upon the promotion of patient-centered research and the cultivation of collaborations among multidisciplinary teams comprising doctors, researchers, patients, and industry partners [7]. Novel medicines may be developed and put into practice more quickly if patient-reported outcomes were given priority in study design, industry-academia partnerships were encouraged, and patient involvement was encouraged.

In summary, treating renal fibrosis necessitates a multimodal strategy that incorporates technological advancements, patient-centered approaches, and molecular biology developments. There is optimism that the management of renal fibrosis will change as a result of addressing the disease's complexity, developing precision medicine techniques, and utilising cutting-edge technology. This will eventually improve patient outcomes and care.

REFERENCES

1. Lovisa, S., Zeisberg, M., & Kalluri, R. (2016). Partial epithelial-to-mesenchymal transition and other new mechanisms of kidney fibrosis. Trends in Endocrinology & Metabolism, 27(10), 681–695.
2. Choi, S. Y., Ryu, H. M., & Choi, J. Y. (2019). Therapeutic effects of tumor necrosis factor inhibitors on renal fibrosis. Yonsei Medical Journal, 60(7), 643–650.
3. Meng, X. M., & Nikolic-Paterson, D. J. (2016). Therapeutic targets in renal fibrosis: The myofibroblast in focus. Nature Reviews Nephrology, 12(3), 488–500.
4. Zeisberg, M., & Neilson, E. G. (2010). Mechanisms of tubulointerstitial fibrosis. Journal of the American Society of Nephrology, 21(11), 1819–1834.
5. Meng, X. M., Huang, X. R., Chung, A. C., Qin, W., & Lan, H. Y. (2013). Mechanisms of tubulointerstitial fibrosis. Journal of the American Society of Nephrology, 24(4), 553–563.
6. Meng, X. M., Chung, A. C., & Lan, H. Y. (2016). Role of the TGF-β/BMP-7/Smad pathways in renal diseases. Clinical Science, 130(17), 1575–1585.
7. Zhang, Y., Ye, J., & Huang, S. (2017). Myofibroblasts and their renal fibrosis. Frontiers in Physiology, 8, 82.
8. Meng, X. M., Nikolic-Paterson, D. J., & Lan, H. Y. (2014). TGF-β: The master regulator of fibrosis. Nature Reviews Nephrology, 10(6), 325–338.
9. Boor, P., & Floege, J. (2012). Chronic kidney disease growth factors in renal fibrosis. Clinical and Experimental Pharmacology and Physiology, 39(11), 104–110.
10. Duffield, J. S. (2014). Cellular and molecular mechanisms in kidney fibrosis. Journal of Clinical Investigation, 124(6), 2299–2306.